---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-10T20:09:56.520432'
end_time: '2026-02-10T20:21:28.351336'
duration_seconds: 691.83
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Neonatal Severe Encephalopathy with Lactic Acidosis and Brain Abnormalities
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 7
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Neonatal Severe Encephalopathy with Lactic Acidosis and Brain Abnormalities
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Neonatal Severe Encephalopathy with Lactic Acidosis and Brain Abnormalities**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Neonatal Severe Encephalopathy with Lactic Acidosis and Brain Abnormalities
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Neonatal Severe Encephalopathy with Lactic Acidosis and Brain Abnormalities**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Plan status update
- We identified the most likely disease entity as an NAD(P)HX-repair encephalopathy in the NELABA spectrum, classically linked to NAXE (APOA1BP) deficiency, but the only directly retrievable primary evidence with full text in our tool run was a 2022 case report of NAXD (NAD(P)HX dehydratase) deficiency, a mechanistically related disorder. Evidence below reflects this accessible source and general NAD(P)HX-repair biology; where the scope is limited, we indicate so. We will welcome additional citations (e.g., OMIM/MONDO entries or recent 2023–2024 reviews) to further refine NAXE-specific details.

Artifact: summary table
| Gene/Protein (HGNC symbol) | Molecular function | Key pathway or GO biological process | Cellular component(s) | Key metabolites (CHEBI names/labels) | Primary cell types (CL labels) | Primary tissues (UBERON labels) | Representative phenotypes (HPO labels) | Typical MRI findings | Triggers/precipitants | Notes on treatment attempts | Evidence |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NAXD | NAD(P)HX dehydratase; repairs hydrated NAD(P)H to NAD(P)H | Nicotinamide nucleotide repair; NAD(P)H metabolic process | Mitochondrion; cytosol | NADHX / NAD(P)HX; NADH; NADPH | Neurons | Brain (cerebrum) | Neonatal encephalopathy; lactic acidosis; seizures; developmental regression | Global cerebral atrophy; thin corpus callosum; variable basal ganglia and white-matter involvement | Febrile illness / infection (clinical decompensation) | Empiric mitochondrial "cocktail" (L‑carnitine, CoQ10, thiamine/riboflavin/vit E), antiepileptics; consideration of niacin (vitamin B3) | DOI: https://doi.org/10.1159/000520553; Published Feb 8, 2022 (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5) |


*Table: A compact, evidence-linked table summarizing the molecular role, affected compartments/cell types, core phenotypes, MRI features, triggers, and reported treatment attempts for NAXD (NAD(P)HX dehydratase) deficiency; useful as a quick reference for NAD(P)HX-repair related neonatal encephalopathies.*

Disease Pathophysiology Research Report

Target disease
- Disease Name: Neonatal severe encephalopathy with lactic acidosis and brain abnormalities (NELABA spectrum; mechanistic overlap with NAD(P)HX repair disorders)
- MONDO ID: Not confirmed in accessible evidence during this run; likely mapped to NAXE/NAXD-related neurometabolic encephalopathies.
- Category: Mendelian

1) Core pathophysiology
- Concept and current understanding: In NAD(P)HX-repair deficiency (illustrated by NAXD deficiency), febrile stress and cellular metabolism generate hydrated forms of NADH/NADPH (NADHX/NAD(P)HX) that inhibit multiple dehydrogenases. NAXD (dehydratase) and NAXE (epimerase) normally reconvert these damaged cofactors to functional NAD(P)H. Loss of function leads to accumulation of inhibitory/toxic NAD(P)HX species, impairing mitochondrial respiration and cellular energy production, resulting in lactic acidosis and neuronal vulnerability with encephalopathy and seizures (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).
- Dysregulated pathways: Nicotinamide nucleotide metabolism/repair; mitochondrial electron transport/oxidative phosphorylation; cellular response to heat/febrile triggers; redox homeostasis (tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).
- Affected cellular processes: Neuronal energy metabolism, dehydrogenase-dependent pathways, maintenance of NAD(P)H pools; downstream excitability and network instability manifesting as seizures; neurodegeneration with cerebral atrophy on imaging (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4).

2) Key molecular players
- Genes/Proteins: NAXD (NAD(P)HX dehydratase; HGNC symbol NAXD). Related pathway gene: NAXE (NAD(P)HX epimerase; HGNC symbol NAXE) by biological analogy, though direct NAXE/NELABA evidence was not accessible in this run (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).
- Chemical entities (selected): NADH (reduced nicotinamide adenine dinucleotide), NADPH (reduced nicotinamide adenine dinucleotide phosphate), hydrated derivatives NADHX/NAD(P)HX (damaged cofactors), lactate (reflecting impaired oxidative metabolism and glycolytic flux) (tuncer2022acasewith pages 2-4). 
- Cell types: Neurons are prominently affected; astrocytes may also be involved given brain energy coupling (inferred from clinical neurodegeneration and seizures) (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4).
- Anatomical locations: Cerebrum/forebrain; corpus callosum; basal ganglia/white matter variably involved across cases; spinal cord typically spared in the single detailed case (normal spine MRI) (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4).

3) Biological processes (GO-like annotations)
- Nicotinamide nucleotide metabolic process; NAD(P)H regeneration; mitochondrial electron transport chain; cellular respiration; response to heat; regulation of neuron apoptotic processes (inferred from neurodegeneration) (tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).

4) Cellular components
- Mitochondrion; cytosol; neuronal soma and processes in affected cortical/subcortical regions (tuncer2022acasewith pages 2-4).

5) Disease progression
- Sequence of events (illustrated by NAXD deficiency): A trigger (often febrile illness) precedes acute deterioration with seizures and encephalopathy; inhibited dehydrogenases and mitochondrial dysfunction provoke lactic acidosis; progressive neurodegeneration manifests with developmental regression and structural brain changes (cerebral atrophy, thin corpus callosum), culminating in high infant mortality in severe cases (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).
- Staging: Neonatal/infantile onset with acute metabolic-neurologic crises; intermittent precipitants (fever/infection) superimposed on a chronic energy deficit; progression to severe encephalopathy (tuncer2022acasewith pages 4-5).

6) Phenotypic manifestations
- Key clinical phenotypes: Neonatal/early-infantile encephalopathy, myoclonic or refractory seizures, hypotonia and loss of head control, developmental arrest/regression, elevated serum and CSF lactate (mild to moderate), possible cardiomyopathy and skin lesions in broader literature; high mortality in early life (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).
- Neuroimaging: Global cerebral atrophy, thin corpus callosum; other series describe basal ganglia and diffuse white/gray matter involvement; absence of diffuse restriction in the index MRI; normal spine MRI (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4).
- Triggers: Febrile illness/infection commonly precipitate or exacerbate neurologic decline (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 4-5).

Ontology-grounded annotations for knowledge base use
- Genes/Proteins (HGNC): NAXD (HGNC:23340). Related pathway: NAXE (HGNC:17359) [note: not evidenced in this run]. (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4)
- GO Biological Processes: nicotinamide nucleotide metabolic process; cellular respiration; mitochondrial electron transport chain; response to heat (tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).
- GO Cellular Components: mitochondrion; cytosol (tuncer2022acasewith pages 2-4).
- Cell types (CL): neurons; astrocytes (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4).
- Anatomical structures (UBERON): brain (cerebrum), corpus callosum; basal ganglia (variable) (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4).
- Chemical entities (CHEBI): NADH; NADPH; lactate; NAD(P)HX (hydrated NAD(P)H; label) (tuncer2022acasewith pages 2-4).
- Phenotypes (HPO): Neonatal encephalopathy; Seizures; Lactic acidosis; Developmental regression; Generalized hypotonia; Abnormal corpus callosum morphology; Cerebral atrophy (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).

Expert opinions and treatment attempts
- Expert interpretation from the case report emphasizes that “mitochondrial cocktail” therapies (e.g., L-carnitine, CoQ10, thiamine, riboflavin, vitamin E) may be reasonable empirical interventions when NAXD deficiency is suspected; literature has suggested niacin (vitamin B3) as a potential adjunct in nicotinamide repair defects, and a longer survival in a case receiving vitamin therapy than an affected sibling was noted in prior reports cited by the authors, although definitive efficacy remains unproven (tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).

Relevant statistics and data (from accessible source)
- Biochemistry: Mildly elevated serum and CSF lactate were documented (serum ~2.7 mmol/L; CSF ~1.6 mmol/L; reference 0.4–1.4) (tuncer2022acasewith pages 1-2).
- Outcomes: Despite seizure control on antiepileptics and supportive measures including a mitochondrial cocktail, the reported infant died by 18 months, underscoring severity (tuncer2022acasewith pages 1-2).

Evidence items (with URLs and dates)
- Tuncer GÖ, Randa NC, Aydin S, Aksoy A. A Case with NAD(P)HX Dehydratase (NAXD) Deficiency: A Newly Defined Mutation in a Novel Neurodegenerative Disorder. Molecular Syndromology. Published online Feb 8, 2022. DOI: 10.1159/000520553. URL: https://doi.org/10.1159/000520553 (tuncer2022acasewith pages 1-2, tuncer2022acasewith pages 2-4, tuncer2022acasewith pages 4-5).

Limitations
- The disease label supplied (NELABA) is classically associated with NAXE deficiency in the literature, but our tool-accessible full-text evidence here centers on NAXD deficiency, a mechanistically related NAD(P)HX-repair disorder with overlapping neonatal encephalopathy, lactic acidosis, and brain MRI abnormalities. We therefore present a mechanistic and phenotypic synthesis grounded in this accessible primary source and highlight where inferences are made. Additional 2023–2024 reviews and OMIM/MONDO entries would allow fuller NAXE-specific mapping in an updated report.


References

1. (tuncer2022acasewith pages 1-2): Gökçen Oz Tuncer, Nadide Cemre Randa, Seren Aydin, and Ayşe Aksoy. A case with nad(p)hx dehydratase (naxd) deficiency: a newly defined mutation in a novel neurodegenerative disorder. Molecular Syndromology, 13:1-5, Feb 2022. URL: https://doi.org/10.1159/000520553, doi:10.1159/000520553. This article has 7 citations and is from a peer-reviewed journal.

2. (tuncer2022acasewith pages 2-4): Gökçen Oz Tuncer, Nadide Cemre Randa, Seren Aydin, and Ayşe Aksoy. A case with nad(p)hx dehydratase (naxd) deficiency: a newly defined mutation in a novel neurodegenerative disorder. Molecular Syndromology, 13:1-5, Feb 2022. URL: https://doi.org/10.1159/000520553, doi:10.1159/000520553. This article has 7 citations and is from a peer-reviewed journal.

3. (tuncer2022acasewith pages 4-5): Gökçen Oz Tuncer, Nadide Cemre Randa, Seren Aydin, and Ayşe Aksoy. A case with nad(p)hx dehydratase (naxd) deficiency: a newly defined mutation in a novel neurodegenerative disorder. Molecular Syndromology, 13:1-5, Feb 2022. URL: https://doi.org/10.1159/000520553, doi:10.1159/000520553. This article has 7 citations and is from a peer-reviewed journal.